Interactive Session - Recurrent Pregnancy Loss and Preimplantation Genetic Screening Errors

Date:October 21, 2014

Time:1:15 pm - 2:15 pm

Location:HCC311 - Hawaii Convention Center


William E. Roudebush, Ph.D. (Chair), University of South Carolina School of Medicine, Greenville

Creighton E. Likes, III, M.D., M.S., Fertility Center of the Carolinas

Dennis Peffley, J.D., Ph.D., University of South Carolina School of Medicine. Greenville

David Wininger, Ph.D., Premier Fertility Center

(Case Presentations with Audience Response)

Needs Assessment and Description
Preimplantation genetic screening (PGS) is rapidly becoming a routine procedure used to determine chromosomal normality in embryos produced through in vitro fertilization (IVF). To maximize the efficiency/ proficiency and to minimize errors of the PGS procedure, many factors need to be considered, including but not limited to cell stage for embryo biopsy and screening protocol. This interactive session will address the best practices options to minimize PGS errors for practicing physicians, nurses, and laboratory staff. 

Learning Objectives
At the conclusion of this session, participants should be able to: 

  1. Summarize need- and evidence-based developments for appropriate use of PGS. 
  2. Describe the techniques used for PGS and identify the factors associated with reducing error rates during this testing. 
ACGME Competency
Patient Care 

A 32-year-old female patient with recurrent miscarriages presents to an infertility physician for a consult. The physician and patient discuss possible treatment options, including in vitro fertilization (IVF) with preimplantation genetic screening (PGS). Included within the discussion are the day of embryo biopsy and the pros and cons of available PGS methodologies and their respective error rates. After participating in this session, in my practice I will choose the following approach to maximize the overall chance of a successful pregnancy outcome:
a. Day-3 biopsy with qPCR
b. Day-3 biopsy with Next-Gen Sequencing
c. Day-3 biopsy with qPCR and Next-Gen Sequencing
d. Day-5 biopsy with qPCR
e. Day-5 biopsy with Next-Gen Sequencing
f. Day-5 biopsy with qPCR and Next-Gen Sequencing
g. Not applicable to my area of practice


View Details
Learn More | Join | Renew
Back to Top